Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) EBITDA (2017 - 2020)

Historic EBITDA for Cogent Biosciences (COGT) over the last 4 years, with Q4 2020 value amounting to -$11.3 million.

  • Cogent Biosciences' EBITDA fell 59360.03% to -$11.3 million in Q4 2020 from the same period last year, while for Dec 2020 it was -$74.8 million, marking a year-over-year decrease of 13509.0%. This contributed to the annual value of -$74.8 million for FY2020, which is 13509.0% down from last year.
  • Latest data reveals that Cogent Biosciences reported EBITDA of -$11.3 million as of Q4 2020, which was down 59360.03% from -$50.0 million recorded in Q3 2020.
  • Cogent Biosciences' 5-year EBITDA high stood at $2.3 million for Q4 2019, and its period low was -$50.0 million during Q3 2020.
  • Moreover, its 4-year median value for EBITDA was -$8.0 million (2018), whereas its average is -$10.4 million.
  • Its EBITDA has fluctuated over the past 5 years, first skyrocketed by 12672.79% in 2019, then tumbled by 59360.03% in 2020.
  • Cogent Biosciences' EBITDA (Quarter) stood at -$6.7 million in 2017, then dropped by 28.61% to -$8.6 million in 2018, then skyrocketed by 126.73% to $2.3 million in 2019, then tumbled by 593.6% to -$11.3 million in 2020.
  • Its EBITDA was -$11.3 million in Q4 2020, compared to -$50.0 million in Q3 2020 and -$7.4 million in Q2 2020.